Kvantify secured its funding round to accelerate hybrid computing technologies, aiming to drastically reduce pharmaceutical research and development costs globally.
AARHUS — Kvantify has officially finalized the second close of its current investment round, accumulating a total of €7 million, equivalent to $8.1 million USD. Financial support for this extension was provided by the European Innovation Council (EIC) Fund alongside Delphinus Venture Capital, an investment entity based in Denmark. The administration at Kvantify plans to allocate this capital directly toward the commercial expansion of its hybrid software infrastructure, which integrates classical and quantum computational methods. This architecture specifically addresses the exponential scaling difficulties traditionally encountered in Molecular Simulation and Drug Design.
Advancing Computational Chemistry
A significant portion of the newly acquired capital will be directed toward scaling Qrunch, a specialized technology introduced by the company in November 2025. Qrunch functions by executing complex Quantum Chemistry workflows utilizing current-generation quantum hardware, which is often characterized by high noise levels and limited qubit coherence.
By connecting advanced quantum processing units with traditional high-performance classical supercomputers, the platform enables scientific researchers to process quantum mechanical equations that remain impossible for standard silicon-based systems to resolve in a practical timeframe. The software effectively divides the computational workload, assigning the most mathematically intense molecular interactions to the quantum processor while managing the broader simulation parameters classically.
Impacting Pharmaceutical Workflows
The primary industrial application for this technology lies within the pharmaceutical sector. Kvantify management indicated that the recent financial injection will allow the enterprise to expand its collaborative agreements with major pharmaceutical manufacturing organizations. The corporate strategy involves transitioning their design-to-simulation frameworks out of the experimental phase and integrating them directly into active industrial production pipelines.
Industry analysts note that the integration of such highly accurate simulation tools is expected to significantly lower the attrition rates commonly seen in early-stage Drug Development. By accurately predicting molecular binding affinities and potential toxicity before physical synthesis occurs, pharmaceutical companies can avoid costly late-stage clinical trial failures, thereby reducing overall research and development expenditures.
European Deep-Tech Strategy
The financial backing from prominent European institutions highlights a broader geopolitical strategy to maintain technological sovereignty. The EIC operates under the mandate of the European Union to identify and support breakthrough innovations. Similarly, Delphinus Venture Capital was established in 2025 with an €80 million capital base, supported heavily by academic and retail institutions including Aarhus University and the Salling Group.
Financial experts view their combined participation in this funding round as a deliberate effort to secure a leading position for Europe within the highly competitive deep-tech sector. The overarching goal is to foster domestic enterprises capable of competing with quantum computing initiatives originating from the United States and Asia.
Bridging the Hardware Gap
Since its establishment in 2022, Kvantify has strategically positioned itself as a critical intermediary layer between rapidly maturing physical quantum processors and the commercial life sciences industry. While fully fault-tolerant quantum computers remain years away from realization, the company focuses on extracting immediate commercial value from existing, imperfect hardware.
By delivering a software platform capable of running realistic Medicinal Chemistry simulations today, the organization aims to translate theoretical quantum advantages into practical, real-world solutions for the healthcare and pharmacology sectors.